Fetal Gender
The test allows for the determination of fetal Rh status early in pregnancy (starting from
8–10 weeks of gestation) as part of prenatal screening for pregnancy complications in Rh-negative women. This enables the timely assessment of the risk for Rh incompatibility and prediction of the risk for hemolytic disease of the fetus and newborn.
Non-invasive prenatal molecular genetic diagnostics
Determining fetal gender early in pregnancy, particularly in the first or early second trimester, can be critically important for families with a history of sex-linked hereditary diseases. In such cases, invasive prenatal diagnostic procedures and the option of medical termination of pregnancy may be considered if a male fetus is found to carry mutations in sex-linked genes, such as in hemophilia or progressive muscular dystrophy types Duchenne or Becker.
Furthermore, knowledge of fetal gender is relevant for a physician when considering the prescription of hormonal therapy to a pregnant woman diagnosed with adrenal hyperandrogenism (e.g., congenital adrenal hyperplasia) or other masculinizing endocrine disorders.
Indications
-
Pregnant women with masculinization syndromes -
Suspected fetal gender determination abnormalities based on ultrasound findings -
Carrier status for hemophilia and other sex-linked disorders
Fetal Gender
The Fetal Gender test is intended for the detection of multi-copy fragment of Y chromosome in samples of cell-free fetal DNA extracted from the blood of pregnant women by real-time PCR.
Biomaterial: peripheral blood.
Find out more
Information
Ask questions
Please note that the specialists of the DNA Technology company provide consultations exclusively to medical specialists on the application and research features. Requests related to the appointment, delivery, or interpretation of tests are not considered. For relevant information, we recommend contacting the laboratory directly.